PRISM DNA Barcode Multiplexing for Mixed Cell Population Assay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the effectiveness of anticancer agents on cancer cells are expensive and laborious, as they require testing individual cell lines, which is not feasible for rapid evaluation of new therapeutics across multiple tumor cell lines.
Innovation Solution
The development of PRISM (Predictive RNA Screening Method) using stably integrated DNA barcode sequences allows for simultaneous assay of multiple cell lines in vitro and in vivo, using nucleic acid tags as unique markers to assess viability and proliferation, thereby reducing time and cost by evaluating cell responses in mixed cell populations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If individual cell lines are tested separately to assess effectiveness of anticancer agents, then measurement precision of each cell line's response is improved, but productivity and cost increase significantly
Solution Approach 1:
Multiple genetically heterogeneous cell lines are pooled together into a single mixture, with each cell line contributing a unique DNA barcode. This merged population allows simultaneous assessment of multiple cell lines in one experiment, dramatically improving productivity while maintaining the ability to precisely measure individual cell line responses through barcode-specific detection
Solution Approach 2:
A universal detection system using common PCR primers and barcode-specific probes enables the same assay platform to measure multiple cell lines simultaneously. The DNA barcode sequences serve as universal markers that can be detected by a single standardized protocol, allowing one system to perform multiple measurement functions
2Measurement precision
If individual cell lines are tested separately to assess effectiveness of anticancer agents, then measurement precision of each cell line's response is improved, but loss of time increases
Solution Approach 1:
Multiple cell line assessments are merged into a single pooled sample that is exposed to the test agent simultaneously. After treatment, all barcode sequences are amplified and quantified in one detection run, reducing the total time required compared to sequential testing of individual cell lines while preserving precise measurement of each cell line's response
Solution Approach 2:
DNA barcode sequences are stably integrated into each cell line's genome before the assay, serving as pre-established unique identifiers. This preliminary tagging allows for rapid simultaneous detection of all cell lines after treatment, eliminating the need for time-consuming individual cell line processing and identification steps
3Productivity
If DNA barcode sequences are used to simultaneously assay multiple cell lines, then productivity is improved, but device complexity increases
Solution Approach 1:
Instead of developing complex individual assays for each cell line, the system uses simplified DNA barcode sequences that can be amplified by standard PCR technology. The barcode sequences are copied millions of times during PCR amplification, allowing detection of rare cell lines within the mixture using conventional, well-established molecular biology techniques rather than requiring new complex devices
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PRISM enables rapid and cost-effective evaluation of therapeutic agents across multiple cell lines, facilitating cancer drug discovery and personalized treatment strategies by identifying new classes of therapeutics and understanding genetic vulnerabilities.
Implementation Method 1
A PCR reaction is performed on a sample comprising a mixed population of cells
Implementation Method 2
A fluorescently labeled detection oligonucleotide is then hybridized to the PCR product
Data Source
AI summary
Methods to simultaneously test and screen multiplexed, mixed cell populations, e.g., populations comprising genetically heterogeneous cancer cells, in common conditions.